| Human immunodeficiency virus I infection
Evotaz vs Sunlenca
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Evotaz vs Sunlenca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSunlenca has a higher rate of injection site reactions vs Evotaz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sunlenca but not Evotaz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Evotaz
Sunlenca
At A Glance
Oral
Once daily
HIV-1 protease inhibitor with CYP3A inhibitor
SC injection
Every 6 months
HIV-1 capsid inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (atazanavir 300 mg/cobicistat 150 mg) orally once daily with food.
Human immunodeficiency virus I infection (Initiation Option 1) Day 1: 927 mg SC injection (2 x 1.5 mL) plus 600 mg oral (2 x 300 mg tablets); Day 2: 600 mg oral (2 x 300 mg tablets); then 927 mg SC every 6 months (26 weeks) for maintenance.
Human immunodeficiency virus I infection (Initiation Option 2) Days 1 and 2: 600 mg oral (2 x 300 mg tablets); Day 8: 300 mg oral (1 x 300 mg tablet); Day 15: 927 mg SC injection (2 x 1.5 mL); then 927 mg SC every 6 months (26 weeks) for maintenance.
Contraindications
- Clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
- Coadministration with strong CYP3A4 inducers
- Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance with narrow therapeutic indices
- Coadministration with alfuzosin
- Coadministration with ranolazine
- Coadministration with dronedarone
- Coadministration with carbamazepine, phenobarbital, phenytoin
- Coadministration with colchicine in patients with hepatic or renal impairment
- Coadministration with rifampin
- Coadministration with apalutamide, encorafenib, irinotecan, ivosidenib
- Coadministration with lurasidone, pimozide
- Coadministration with dihydroergotamine, ergotamine, methylergonovine
- Coadministration with elbasvir/grazoprevir, glecaprevir/pibrentasvir
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with drospirenone/ethinyl estradiol
- Coadministration with lomitapide, lovastatin, simvastatin
- Coadministration with nevirapine
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with indinavir
- Coadministration with triazolam, orally administered midazolam
- Concomitant use of strong CYP3A inducers
Adverse Reactions
Most common (>=5%) Jaundice, rash
Serious Cardiac conduction abnormalities, rash, effects on serum creatinine, new onset or worsening renal impairment, chronic kidney disease, nephrolithiasis, cholelithiasis, hepatotoxicity, hyperbilirubinemia
Most common (>=3%) Injection site reactions, nausea
Serious Grade 3 injection site reactions (erythema, pain, swelling)
Postmarketing Injection site necrosis
Pharmacology
EVOTAZ is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that prevents viral Gag and Gag-Pol polyprotein processing, and cobicistat, a CYP3A inhibitor that increases atazanavir systemic exposure.
Lenacapavir is a multistage, selective HIV-1 capsid inhibitor that directly binds to capsid protein (p24) subunits in hexamers, inhibiting multiple essential steps of the viral lifecycle including capsid-mediated nuclear uptake of proviral DNA, virus assembly and release, and capsid core formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Evotaz
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Sunlenca
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Evotaz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Sunlenca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Evotaz
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Sunlenca
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Gilead Advancing Access Co-Pay Program: SunlencaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EvotazView full Evotaz profile
SunlencaView full Sunlenca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.